Home > Newsletters > FDAnews Drug Daily Bulletin > FDA Wants Harder Approval Standards for Drug-Device Combo Diagnostics
FDAnews Drug Daily Bulletin
June 12, 2012 | Vol. 9 No. 115
FDA Wants Harder Approval Standards for Drug-Device Combo Diagnostics
Pharma companies seeking approval for drugs along with companion diagnostics could see more streamlined FDA decisions as the agency moves toward a stricter preapproval path for the diagnostic portion of companion products. The FDA is moving toward requiring premarket approval (PMA) applications for companion diagnostics, rather than the less stringent 510(k) or de novo 510(k) applications that are most often used now, said Christine Gathers, senior director of regulatory affairs for Eli Lilly.
Washington Drug Letter
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.